Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
CDKN2A and prostate cancer are reported together in 1 article.
Gene
CDKN2A
- HGNC
- HGNC:1787
48articles
48mentions
0variants with confirmed gene link
Most co-reported phenotypes (articles)
Phenotype
Prostate cancer
218articles
218mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
1 records shown · first 60Genomic profiling of urological malignancies using tissue-based next generation sequencing.
PMID 40410007 | DOI 10.1016/j.urolonc.2025.04.011 · Urologic oncology · 2025 · 9 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CDKN2A | “Prostate cancer commonly involves TMPRSS2-ERG fusions and BRCA2 mutations, affecting treatment strategies, and penile squamous cell carcinoma follows distinct HPV-dependent and HPV-independent pathways, with mutations in TP53 and CDKN2A genes.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “Prostate cancer commonly involves TMPRSS2-ERG fusions and BRCA2 mutations, affecting treatment strategies, and penile squamous cell carcinoma follows distinct HPV-dependent and HPV-independent pathways, with mutations in TP53 and CDKN2A genes.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | VHL | “For instance, renal cell carcinoma frequently harbors alterations in VHL, PBRM1, and BAP1, influencing therapeutic responses, while urothelial carcinoma is characterized by FGFR3 mutations and TERT promoter alterations, which have implications for targeted therapy.” | 0.98 | hgnc_dict_v1 |
| gene | PBRM1 | “For instance, renal cell carcinoma frequently harbors alterations in VHL, PBRM1, and BAP1, influencing therapeutic responses, while urothelial carcinoma is characterized by FGFR3 mutations and TERT promoter alterations, which have implications for targeted therapy.” | 0.98 | hgnc_dict_v1 |